Phthalide derivatives as dihydrofolate reductase inhibitors for malaria: molecular docking and molecular dynamics studies

Abstract

Plasmodium falciparum dihydrofolate reductase enzyme (P. falciparum DHFR) is one of the vital drug targets for malaria treatment, as this protein is indispensable for nucleotide metabolic pathways. This research aimed to discover promising phthalide derivatives against both wild and mutant P. falciparum DHFR enzymes through various computational techniques. The binding affinities were investigated using molecular docking, which showed five compounds having the highest affinity scores against both enzymes compared to the reference compounds. MM-GBSA calculations displayed favourable free binding energy. Moreover, the ADMET properties of the compounds are within acceptable ranges. The stability of the ligand-protein complexes was studied by Molecular Dynamics (MD) simulations. Depending on the results obtained from this research, we propose three compounds to be hit against P. falciparum DHFR activity which could be examined experimentally.

Communicated by Ramaswamy Sarma

Keywords:

• Malaria
• phthalide derivatives
• dihydrofolate reductase
• docking
• molecular dynamics

Acknowledgement

We acknowledge Mme Katia Dekimeche from Schrödinger for her support and help.

Disclosure statement

The authors declare that there are no conflicts of interest.

Funding

The author(s) reported there is no funding associated with the work featured in this article.